Indoco Remedies reappoints Aditi Panandikar as MD for 5 years

Management Changes View source PDF Explain this filing

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-7.7%Reaction day

₹248.00

prior close

₹260.88

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.3%-6.4% vs market

Pharmaceuticals peers, median of 165sector-0.8%-6.9% vs sector

On the reaction day the stock moved 6.4 pts less than Nifty Microcap 250 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-2.1

15m

-2.4

30m

-7.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-7.7-1.3-6.4-0.8-6.9

Next day

-9.7-0.8-8.9+0.3-9.9

-12.3-1.4-10.9-0.7-11.6

-11.3-0.3-11.0-0.3-11.1

-10.5+1.0-11.5+0.3-10.8

-10.0+1.5-11.4+0.7-10.7

-10.9+3.1-14.0+0.3-11.2

15d

-10.7+4.1-14.8+1.1-11.8

+0.0+4.8-4.7+1.6-1.5

+0.3+3.1-2.9+2.4-2.1

-13.6-3.6-10.0-2.0-11.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Indoco Remedies board has approved the reappointment of Ms. Aditi Panandikar as Managing Director for 5 years, from February 15, 2027 to February 14, 2032, pending shareholder approval at the 79th AGM. She is the daughter of Chairman Suresh G Kare and holds over 30 years of pharma industry experience. The board also appointed Mr. Sudhir Kadam as Sr. VP (Human Capital) effective July 28, 2026.

Likely market impact

Leadership continuity as promoter family member Aditi Panandikar gets a fresh 5-year term as Managing Director, subject to shareholder approval.